



European
Helicobacter &
Microbiota
Study
Group

XXXIInd International Workshop on Helicobacter & Microbiota in Inflammation and Cancer

EHMSG Postgraduate Course

“Microbiota: from metabolism to immunity and fecal microbial transplantation - pearls for the clinician”

September 5 – 7, 2019 | Innsbruck | Austria



Final Programme

www.ehmsg.org



European
Helicobacter &
Microbiota
Study
Group

XXXIInd International Workshop on Helicobacter & Microbiota in Inflammation and Cancer

EHMSG Postgraduate Course

“Microbiota: from metabolism to immunity and fecal microbial transplantation - pearls for the clinician”

September 5 – 7, 2019 | Innsbruck | Austria

a member of

UNITED EUROPEAN
GASTROENTEROLOGY
ueg



TABLE OF CONTENTS

4

Awardees of the Marshall and Warren Medal	4
Welcoming Address	5
Committees – Organisation	6
Workshops of the EHMSG	6
Map of the Conference Venue	7
Programme at a Glance	8-9
Scientific Programme	
- Thursday, September 5	10-11
- Friday, September 6	12-17
- Saturday, September 7	18-21
Sponsored Satellite Symposium	22
Scientific Information	
- Oral Presentations	23
- Poster Presentations	24
Acknowledgements	25
General Information	26
- Registration Details	28
- Networking Events	29

AWARDEES OF THE MARSHALL AND WARREN MEDAL

2019	Guillermo Perez-Perez, New York, NY, United States
2018	Kenneth McColl, Glasgow, United Kingdom
2017	Jean-Charles Delchier, France
2016	Ken Sugano, Shimotsuke, Japan
2015	Heidi-Ingrid Maaroos, Tartu, Estonia
2014	Manfred Kist, Freiburg, Germany
2013	Masahiro Asaka, Sapporo, Japan
2012	Richard Hunt, Hamilton, ON, Canada
2011	Samy Cadranel, Brussels, Belgium
2010	Reinhold W. Stockbrügger, Maastricht, The Netherlands
2009	Pelayo Correa, Nashville, TN, United States
2008	Timo Kosunen, Helsinki, Finland
2007	Mike Dixon, Leeds, United Kingdom
2006	Barry Marshall, Perth, Australia & Stanislaw Konturek, Cracow, Poland

NEXT EHMSG WORKSHOP

Glasgow, United Kingdom | September 10 - 12, 2020

Welcoming address by the President of the European Helicobacter and Microbiota Study Group Prof. Dr. Herbert Tilg

Dear Colleagues, dear friends,

A warm welcome from my side to the annual meeting of EHMSG in Innsbruck, Austria. EHMSG has evolved over the last years as a very dynamic and innovative international society and now tries to cover in its annual meeting both highlights and recent developments from the „Helicobacter“ and „microbiota“ field.



It is my pleasure to announce that we were able to organize a world-class postgraduate course on gut microbiota on September 5th covering very diverse aspects of microbiota research. Top international and highly respected colleagues will present their state-of-the-art research. In the original programme of this meeting excellent original research from both the Helicobacter and microbiota field will be presented.

Innsbruck, a small but wonderful city in the heart of the Alps is a perfect host for such an international meeting. Our congress venue is located in the middle of the city and constitutes a perfect location for this type of meeting. We are proud to welcome colleagues from all over the world to attend this year's EHMSG meeting. The special and almost familiar atmosphere of this meeting will allow to enjoy not only top science but also friendship and loveliness of our city and country.

With my best wishes

Herbert Tilg
President of EHMSG



European Helicobacter & Microbiota Study Group EHMSG

President of the EHMSG

Herbert Tilg, Austria

Members and International Scientific Committee

Leif P. Andersen, Denmark
Lars Engstrand, Sweden
Antonio Gasbarrini, Italy
Javier P. Gisbert, Spain
Georgina Hold, United Kingdom
Ernst Kuipers, The Netherlands
Marcis Leja, Latvia
José C. Machado, Portugal
Peter Malfertheiner, Germany
Francis Mégraud, France
Colm A. O'Morain, Ireland
Mirjana Rajilic-Stovanovic, Serbia
Ari P. Ristimäki, Finland
Theodore Rokkas, Greece
Annemieke Smet, Belgium

Emeritus Members

Anthony Axon, United Kingdom
Michel A.L. Deltenre, Belgium
Bram Flahou, Belgium
Giovanni Gasbarrini, Italy
Alexander M. Hirschl, Austria
Pierre Michetti, Switzerland
José M. Pajares Garcia, Spain
Ashley B. Price, United Kingdom
Mario G. Quina, Portugal (†)
Erik A.J. Rauws, The Netherlands
Pentti I. Sipponen, Finland
Torkel M. Wadström, Sweden

Honorary Members

Franco Bazzoli, Italy
James G. Fox, United States
David Y. Graham, United States
Adrian Lee, Australia
Barry Marshall, Australia
Guido N.J. Tytgat, The Netherlands

Local Committee

President

Herbert Tilg, Austria

Members

Timon Adolph, Innsbruck
Werner Dolak, Vienna
Maria Effenberger, Innsbruck
Christoph Högenauer, Graz
Günter Krejs, Graz
Patrizia Kump, Graz
Athanasios Makristathis, Vienna
Alexander Moschen, Innsbruck
Christoph Steininger, Vienna

Corresponding Fellows

Niyaz Ahmed, India
Dmitry Bordin, Russia
Luis G. Vaz Coelho, Brazil
Jae Gyu Kim, Korea
Varocha Mahachai, Thailand
Yaron Niv, Israel
Chun-Ying Wu, Taiwan
Yoshio Yamaoka, Japan
Weicheng You, China

Organizing Office

Core Agency

Scientific and Administrative Secretariat

Vienna Medical Academy
Catherine Tomek
Alser Strasse 4
A-1090 Vienna, Austria
Phone: +43 1 405 13 83 18
Fax: +43 1 407 82 74
Email: workshop@ehmsg.org

Workshops of the EHMSG

- Bordeaux (1988)
- Ulm (1989)
- Toledo (1990)
- Bologna (1991)
- Dublin (1992)
- Brussels (1993)
- Houston (1994)
- Edinburgh (1995)
- Copenhagen (1996)
- Lisbon (1997)
- Budapest (1998)
- Helsinki (1999)
- Rome (2000)
- Strasbourg (2001)
- Athens (2002)
- Stockholm (2003)
- Vienna (2004)
- Copenhagen (2005)
- Wroclaw (2006)
- Istanbul (2007)
- Riga (2008)
- Porto (2009)
- Rotterdam (2010)
- Dublin (2011)
- Ljubljana (2012)
- Madrid (2013)
- Rome (2014)
- Nicosia (2015)
- Magdeburg (2016)
- Bordeaux (2017)
- Kaunas (2018)
- **Innsbruck (2019)**



European
Helicobacter &
Microbiota
Study
Group

XXXIIIrd International Workshop

on Helicobacter & Microbiota in Inflammation and Cancer

September 10 – 12, 2020 | Glasgow | United Kingdom



Invitation

www.ehmsg.org

SAVE THE DATE!



Thursday, September 5, 2019

08.00 - 17.00 hrs	EHMSG Postgraduate Course “Microbiota: from metabolism to immunity and fecal microbial transplantation-pearls for the clinician”	Room Brussels
17.00 - 18.30 hrs	EHMSG Far East Symposium Omics for Helicobacter	Room Brussels
18.30 - 19.30 hrs	Networking Event	Exhibition Area of the Conference Venue

Friday, September 6, 2019

08.30 – 19.15 hrs	EHMSG 2019 Conference	Room Innsbruck
08.30 – 09.30 hrs	Introductory Lectures	Room Innsbruck
09.30 – 11.10 hrs	Symposium: Microbiota and GI/liver cancer	Room Innsbruck
11.10 – 11.30 hrs	Coffee Break	Exhibition Area
11.30 – 13.10 hrs	Symposium: Gastric Carcinogenesis	Room Innsbruck
13.10 – 14.00 hrs	Lunch Break & Poster Viewing	Exhibition Area
14.00 – 14.30 hrs	Impact of <i>H. pylori</i> eradication on gastric cancer risk	Room Innsbruck
14.30 – 16.00 hrs	Parallel Workshops from Submitted Abstracts Workshop W1. Diagnosis & Epidemiology	Room Innsbruck
14.30 – 16.00 hrs	Parallel Workshops from Submitted Abstracts Workshop W2. <i>H. pylori</i> pathogenesis	Room Brussels
16.00 – 16.30 hrs	Coffee Break	Exhibition Area
16.30 – 17.30 hrs	State of the Art Lectures	Room Innsbruck
17.30 – 19.15 hrs	Parallel Workshops from Submitted Abstracts Workshop W3. Treatment of Helicobacter Infection I	Room Innsbruck
17.30 – 19.15 hrs	Parallel Workshops from Submitted Abstracts Workshop W4. Gastric Carcinogenesis	Room Brussels
20.00 hrs	Networking Dinner	Restaurant Stiftskeller

Saturday, September 7, 2019

08.00 – 18.30 hrs	EHMSG 2019 Conference	Room Innsbruck
08.00 – 09.40 hrs	Symposium: Modulation of microbiota	Room Innsbruck
09.40 – 10.30 hrs	Coffee Break	Exhibition Area
10.30 – 12.00 hrs	Symposium: Helicobacter and other Microbiota in Extragastric Diseases	Room Innsbruck
12.00 - 13.00 hrs	Industry-Sponsored Satellite Symposium	Room Innsbruck
13.00 – 14.00 hrs	Lunch Break & Poster Viewing	Exhibition Area
14.00 – 15.30 hrs	Parallel Workshops from Submitted Abstracts Workshop W5. Treatment of Helicobacter Infection II	Room Innsbruck
14.00 – 15.30 hrs	Parallel Workshops from Submitted Abstracts Workshop W6. Microbiota in Health and Disease	Room Brussels
15.30 – 16.00 hrs	Coffee Break	Exhibition Area
16.00 – 17.30 hrs	Symposium: Treatment of <i>H. pylori</i> infection	Room Innsbruck
17.30 – 18.00 hrs	Debate: Is <i>Helicobacter pylori</i> relevant in oesophageal diseases?	Room Innsbruck
18.00 – 18.30 hrs	Closing Session Awarding of the Marshall and Warren Medal to Guillermo Perez-Perez (New York, NY, USA) EHMSG Presentation and Poster Awards Presentation of the next meeting EHMSG 2020 in Glasgow, United Kingdom Closing remarks	Room Innsbruck





EHMSG Postgraduate Course

“Microbiota: from metabolism to immunity and fecal microbial transplantation-pearls for the clinician”

Course directors: Antonio Gasbarrini, Herbert Tilg

Room Brussels

08.00 – 09.35 hrs

Opening session: State-of-the art lectures

Chair: Antonio Gasbarrini, Herbert Tilg

08.00 - 08.05

Welcome

Herbert Tilg, Innsbruck, Austria | Antonio Gasbarrini, Rome, Italy

08.05 - 08.35

What is a healthy microbiome?

Julian Marchesi, London, United Kingdom

08.35 - 09.05

The gut microbiota as major player in metabolic disorders

Fredrik Bäckhed, Gothenburg, Sweden

09.05 - 09.35

Microbiota-driven personalized medicine: close to reality?

Eran Elinav, Rehovot, Israel

09.35 - 10.05 hrs

Coffee Break

10.05 - 11.45 hrs

The gut microbiota as complex ecosystem: from “big data” to clinical reality

Chair: Georgina Hold, Marcis Leja

10.05 - 10.30

Microbiota signatures for various diseases: are we there yet?

Lars Engstrand, Stockholm, Sweden

10.30 - 10.55

What can be learn from population-based microbiota studies?

Marie Joossens, Leuven, Belgium

10.55 - 11.20

Gut epithelial barrier dysfunction and evidence for a circulating microbiome

Remy Burcelin, Toulouse, France

11.20 - 11.45

Antibiotics: not only detrimental for the microbiota

Gianluca Ianiro, Rome, Italy

11.45 – 13.00 hrs

Lunch Break

13.00 – 14.40 hrs

Inflammatory bowel disorders (IBD) and intestinal microbiota

Chair: Patrizia Kump, Lars Engstrand

13.00 - 13.25

Gut microbiota composition and IBD: what have we learned?

Harry Sokol, Paris, France

13.25 - 13.50

Pro- and prebiotics in IBD

Alessandro Armuzzi, Rome, Italy

13.50 - 14.15

Biomarkers associated with FMT outcomes

Nadeem Kaakoush, Sydney, Australia

14.15 - 14.40

Faecal microbial transplantation (FMT) and IBD

Patrizia Kump, Graz, Austria

14.40 - 15.15 hrs	Coffee Break
15.15 – 16.55 hrs	FMT: solution for many disorders? <i>Chair: Juozas Kupcinskas, Colm O'Morain</i>
15.15 - 15.40	FMT for <i>Clostridium difficile</i> and other antibiotics-resistant bacteria Giovanni Cammarota, Rome, Italy
15.40 - 16.05	FMT for metabolic syndrome, obesity and diabetes Max Nieuwdorp, Amsterdam, The Netherlands
16.05 - 16.30	FMT: a role in cancer immunotherapy? Patricia Lepage, Jouy-en-Josas, France
16.30 - 16.55	FMT in chronic liver diseases and complications Jasmohan S. Bajaj, Richmond, VA, USA
16.55 - 17.00 hrs	Closing

EHMSG Far East Symposium

“Omics for Helicobacter”

Chairs: Sang Woo Lee, Francis Mégraud, Kentaro Sugano

Room Brussels

17.00 - 18.30 hrs

Dynamics of *H. pylori* genome and methylome variation during early and chronic infection

Sebastian Suerbaum, Munich, Germany

Current knowledge of genomics for *H. pylori* from Far East

Yoshio Yamaoka, Oita, Japan

Dynamics of microbial communities in the human stomach and a humanized gastric microbiota mouse model

Soon-Kyeong Kwon, Gyeongsang, South Korea

18.30 - 19.30 hrs

EHMSG 2019 Welcome Reception



08.30 - 09.30 hrs

Introductory Lectures

Room Innsbruck

Chair: Franco Bazzoli, Herbert Tilg

08.30 - 09.00

What's hot in *Helicobacter pylori*?

Kentaro Sugano, Japan

09.00 - 09.30

What's hot in Microbiota?

Eran Elinav, Rehovot, Israel

09.30 - 11.00 hrs

Symposium: Microbiota and GI/liver cancer

Room Innsbruck

Chair: Lars Engstrand, Herbert Tilg

09.30 - 09.50

Gastro-duodenal dysbiosis in functional dyspepsia: the missing link?

Carmelo Scarpignato, Parma, Italy

09.50 - 10.10

Microbiota and its role in oesophageal and gastric cancer

Ceu Figueiredo, Porto, Portugal

10.10 - 10.30

H. pylori infections and associated (pre)malignant lesions of the stomach

Michiel Mommersteeg, Amsterdam, The Netherlands

10.30 - 10.50

Microbiota & Liver cancer

Francesca Romana Ponziani, Rome, Italy

10.50 - 11.10

Cancer therapies and microbiota

Georgina Hold, Sydney, Australia

11.10 – 11.30 hrs

Coffee Break

11.30 - 13.10 hrs

Symposium: Gastric Carcinogenesis

Room Innsbruck

Chair: Yong Chan Lee, Ari Ristimäki

11.30 - 11.50

Do animal models provide answers in gastric carcinogenesis?

James Fox, Boston, MA, US

11.50 - 12.10

Immunopathogenesis in gastric cancer

Mario Milco D'Elia, Florence, Italy

The role of intestinal metaplasia in gastric carcinogenesis:

12.10 - 12.30

The endoscopic & clinical approach

Mario Dinis-Ribeiro, Porto, Portugal

12.30 - 12.50

The histopathological approach

Massimo Rugge, Padova, Italy

12.50 – 13.10

The molecular approach

Ki-Taek Nam, Seoul, Korea

13.10 – 14.00 hrs

Lunch Break Poster Viewing

14.00 - 14.30 hrs

Impact of *H. pylori* eradication on gastric cancer risk

Room Innsbruck

Chair: Jae Gyu Kim, Marcis Leja

In the East

Il Ju Choi, Seoul, Korea

In the West

Theodore Rokkas, Athens, Greece

14.30 - 16.00 hrs

Parallel Workshops from Submitted Abstracts 1

Room Innsbruck

Workshop W1. | Diagnosis and Epidemiology

Chair: Theodore Rokkas, Christoph Steininger

Each presentation is scheduled for 12 minutes (9 min presentation + 3 min discussion)

W1.1

Apparent intracellular *Helicobacter pylori* detected by immunohistochemistry - the missing link in eradication failure

A. Beer¹, H. Hudler², M. Kundi¹, S. Hudler², M. Hader³, V. Taeuber¹, H. Schachner¹, S. Gruber², A. M. Hirschl¹, R. Kain¹, A. Makristathis¹, ¹Medical University Vienna, Vienna, Austria, ²Histopathologic practice Winzendorf, Winzendorf, Austria, ³Wilhelminenspital, Vienna, Austria.

W1.2

Impact of implementing a real-time PCR assay on the workflow and laboratory diagnosis of *Helicobacter pylori* infection from gastric biopsies

T. Huang, P. Bogaerts, M. Hoebeke, W. Bouchahrouf, C. Berhin, Y. Glupczynski, National Reference Center for *Helicobacter pylori*, Yvoir, Belgium.

W1.3

Impaired sensitivity of invasive tests for *Helicobacter pylori* infection in patients with severe chronic atrophic gastritis

L. Koletzko¹, K. Schütte², L. Macke¹, R. Vasapolli¹, A. Link³, P. Malfertheiner¹, C. Schulz¹, ¹Department of Medicine II, University Hospital, LMU Munich, München, Germany, ²Department of Internal Medicine and Gastroenterology, Niels-Stensen-Kliniken, Osnabrück, Germany, ³Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Magdeburg, Germany.

W1.4

Risk of gastrointestinal bleeding in new or chronic aspirin users after treatment for *Helicobacter pylori* : A territory-wide cohort study

C. Guo, K. S. Cheung, E. W. Chan, I. C. Wong, W. K. Leung, University of Hong Kong, Hong Kong, Hong Kong.

W1.5

Racial differences in *Helicobacter pylori* antibody prevalence by year of birth and demographic factors in a consortium of US adults

M. G. Varga¹, J. Butt², W. J. Blot³, L. Le Marchand⁴, C. Haiman⁵, Y. Chen⁶, S. Wassertheil-Smoller⁷, G. Y. F. Ho⁸, L. E. Tinker⁹, R. M. Peek³, J. D. Potter⁹, T. L. Cover³, L. Hendrix², T. Hyslop², A. Zeleniuch-Jacquotte⁶, S. Berndt¹⁰, A. Hildesheim¹⁰, T. Waterboer¹¹, M. Pawlita¹¹, M. Epplen², ¹University of North Carolina, Chapel Hill, NC, United States, ²Duke Cancer Institute, Durham, NC, United States, ³Vanderbilt University Medical Center, Nashville, TN, United States, ⁴University of Hawaii Cancer Center, Honolulu, HI, United States, ⁵University of Southern California, Los Angeles, CA, United States, ⁶New York University, New York, NY, United States, ⁷Albert Einstein College of Medicine, Bronx, NY, United States, ⁸Northwell Health, Great Neck, NY, United States, ⁹Fred Hutchinson Cancer Research Center, Seattle, WA, United States, ¹⁰National Cancer Institute, Rockville, MD, United States, ¹¹German Cancer Research Center, Heidelberg, Germany.

W1.6

Seroprevalence and determinants of *Helicobacter pylori* infection in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

S. H. Tsang¹, M. Avilés-Santa², C. C. Abnet¹, M. O. Brito³, R. D. Burk⁴, M. L. Daviglius³, S. Wassertheil-Smoller⁴, S. Castaneda⁵, B. I. Graubard¹, B. Thyagarajan⁶, M. Camargo¹, ¹National Cancer Institute, Rockville, MD, United States, ²National Institute on Minority Health and Health Disparities, Rockville, MD, United States, ³University of Illinois, Chicago, IL, United States, ⁴Albert Einstein College of Medicine, Bronx, NY, United States, ⁵San Diego State University, Calexico, CA, United States, ⁶University of Minnesota, Minneapolis, MN, United States.



W1.7

Decreased pepsinogen level in relation to presence of menopause in the GISTAR study population in Latvia

J. Aleksejeva¹, D. Razuka-Ebela^{1,2}, I. Daugule^{1,2}, I. Polaka², S. Parshutin², D. Santare^{1,2}, I. Ebela¹, R. Murillo³, R. Herrero³, J. Park³, M. Leja^{1,2}, ¹Faculty of Medicine, University of Latvia, Riga, Latvia, ²Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia, ³International Agency for Research on Cancer, Lyon, France.

14.30 - 16.00 hrs

Parallel Workshops from Submitted Abstracts 2

Workshop W2. | *H. pylori* and pathogenesis

Room Brussels

Chair: Annemieke Smet, Christine Josenhans

Each presentation is scheduled for 12 minutes (9 min presentation + 3 min discussion)

W2.1

R-Spondin 3 links gastric epithelial stem cell regeneration to antimicrobial defense against *Helicobacter pylori*

M. Sigal^{1,2}, T. Meyer¹, ¹Max-Planck-Institute for Infection Biology, Berlin, Germany, ²Charité University Medicine Berlin, Department of Gastroenterology, Berlin, Germany.

W2.2

Helicobacter pylori CagA induces intestinal metaplasia in normal human gastric epithelial cells

T. Meyer, M. Reines, Department of Molecular Biology; Max Planck Institute for Infection Biology, Berlin, Germany.

W2.3

Inhibition of Autophagy aggravates DNA damage response via Rad51 ubiquitination in response to *H. pylori* infection.

C. Xie, N. Li, H. Wang, C. He, Y. Hu, C. Peng, J. Chen, X. Shu, Y. Zhu, N. Lu, Department of Gastroenterology, Nanchang, China.

W2.4

The innate immune molecule NLRC5 protects against *Helicobacter*-induced gastric B cell lymphomagenesis

M. Chonwerawong¹, J. Ferrand¹, H. Chaudhry¹, C. Higgins¹, L. Tran¹, M. Walker², P. S. Bathal³, A. Dev⁴, G. Moore⁴, W. Sievert⁴, B. J. Jenkins¹, M. D'Elia⁵, D. J. Philpott⁶, T. A. Kufer⁷, R. L. Ferrero¹, ¹Hudson Institute of Medical Research, Monash University, Melbourne, Australia, ²The University of Newcastle, Newcastle, Australia, ³University of Melbourne, Melbourne, Australia, ⁴Monash Health, Monash University, Melbourne, Australia, ⁵University of Florence, Florence, Italy, ⁶University of Toronto, Toronto, ON, Canada, ⁷University of Hohenheim, Stuttgart, Germany.

W2.5

DNA hypermethylation downregulates Telomerase Reverse Transcriptase (TERT) during *H. pylori*-induced chronic inflammation.

F. I. Bussière¹, V. Michel², J. Fernandes², L. Costa^{2,3}, V. Camilo², H. De Reuse², L. Fiette^{2,4}, E. TOUAT², ¹INRA, Nouzilly, France, ²Institut Pasteur, Paris, France, ³Institut Cochin, Paris, France, ⁴Institut Mutualiste Montsouris, Paris, France.

W2.6

Helicobacter pylori dampens MHC-II expression on macrophages via the up-regulation of miRNAs targeting CIITA

M. de Bernard, G. Codolo, M. Toffoletto, F. Chemello, S. Coletta, G. Soler Teixidor, G. Battaggia, G. Munari, M. Fassan, S. Cagnin, University of Padova, Padova, Italy.

W2.7

H. pylori epigenome micro-evolution associated with DNA methyltransferases' sequence-specificity changes

M. Fukuyo^{1,2}, H. Yano^{3,4}, H. Yonezawa⁵, N. Takahashi⁵, K. Yahara⁶, M. Konno⁷, T. F. Shibata⁸, S. Shigenobu⁸, B. Rahmutulla¹, I. Uchiyama⁸, Y. Hasegawa², O. Ohara², A. Kaneda¹, I. Kobayashi^{3,5,9}, ¹Chiba University, Chiba, Japan, ²Kazusa DNA Research Institute, Kisarazu, Japan, ³The University of Tokyo, Tokyo, Japan, ⁴Tohoku University, Sendai, Japan, ⁵Kyorin University, Tokyo, Japan, ⁶National Institute of Infectious Diseases, Tokyo, Japan, ⁷Sapporo Kosei General Hospital, Sapporo, Japan, ⁸National Institute for Basic Biology, Okazaki, Japan, ⁹University Paris-Saclay, Paris, France.

16.00 – 16.30 hrs

Coffee Break

16.30 - 17.30 hrs

State of the Art Lectures

Room Innsbruck

Chair: Luiz Coelho, Giovanni Gasbarrini

“Test and Treat” strategy with urea breath test: a cost-effective strategy for the management of Hp infection in Spain

Ariel Beresniak, Geneva, Switzerland

The Gut-Brain Axis

Annemieke Smet, Antwerp, Belgium

17.30 - 19.15 hrs

Parallel Workshops from Submitted Abstracts 3

Workshop W3. | Treatment of Helicobacter Infection I

Room Innsbruck

Chair: Francesco di Mario, Jong Jae Park

Each presentation is scheduled for 12 minutes (9 min presentation + 3 min discussion)

W3.1

Is *Helicobacter pylori* cure a life-long strategy? A 25 years survey on 693 patients

F. Di Mario¹, A. Barchi¹, M. Russo¹, M. Franceschi², N. Dal Bò³, R. Cannizzaro⁴, C. Miraglia¹, A. Tursi⁵, G. Brandimarte⁶, P. Crafa¹, L. Franzoni¹, M. Rugge⁷, ¹University of Parma-Department of Medicine and Surgery, Parma, Italy, ²Azienda ULSS 7 Pedemontana, Endoscopy Unit-Ospedale Alto Vicentino, Santorso (VI), Italy, ³Gastroenterology and Gastrointestinal Endoscopy Unit, Treviso Hospital, Treviso, Italy, ⁴Oncological Gastroenterology, CRO Aviano National Cancer Institute, Aviano, Italy, ⁵Gastroenterology Service, ASL BAT, Andria, Italy, ⁶Division of Internal Medicine and Gastroenterology, „Cristo Re“ Hospital, Rome, Italy, ⁷Department of Pathology, University of Padova, Padova, Italy.

W3.2

High efficacy of 14-day high-dose PPI bismuth-containing quadruple therapy with probiotics supplement for *Helicobacter pylori* eradication in high clarithromycin resistance areas: A double blinded-randomized placebo-controlled study.

P. Poonyam^{1,2}, R. Vilaichone^{2,3,4}, P. Chotivitayatarakorn^{2,3,4}, V. Mahachai³, ¹Gastroenterology unit, Faculty of medicine, Srinakharinwirot University, Nakorn Nayok, Thailand, ²Gastroenterology Unit, Thammasat University Hospital, Pathumthani, Thailand, ³National Digestive Diseases Research Center of Thailand, Pathumthani, Thailand, ⁴Department of Medicine, Chulabhorn International College of Medicine (CICM) at Thammasat University, Pathumthani, Thailand.

W3.3

The comparison of effectiveness of standard triple therapy and high-dose amoxicillin/ bismuth therapy in eradication of *H. pylori*

O. Sjomina^{1,2}, A. Lielausa¹, A. Rūdule², E. Martinsone², D. Pūpolā^{2,3}, R. Vangravs², A. Kiršners², S. Paršutins², H. Gorskis², I. Poļaka², A. Jeniceka¹, E. Cine¹, G. Šķenders², D. Razuka-Ebela¹, M. Leja^{1,2,4}, ¹Faculty of Medicine, University of Latvia, Riga, Latvia, ²Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia, ³Latvian Biomedical Research and Study centre, Riga, Latvia, ⁴Digestive Diseases Centre GASTRO, Riga, Latvia.

W3.4

A multi-center real-life study on comparison between bismuth quadruple (BQ) (10 days) and clarithromycin (CLA) containing non-bismuth quadruple (CT) therapy (10 and 14 days) in the eradication of *H. pylori* infection in patients naïve to treatment in a region with high CLA and dual resistance

A. G. Gravina¹, R. M. Zagari², G. Nardone³, A. Federico¹, M. Dallio¹, M. Martorano⁴, C. Mucherino⁵, A. Romiti², L. Avallone¹, L. Granata¹, L. Colacino¹, A. Facchiano¹, D. Picascia¹, D. Sgambato¹, A. Miranda¹, L. Romano⁶, C. Loguercio¹, M. Romano¹ ¹Division of Hepatogastroenterology, Department of Precision Medicine, University of Campania „Luigi Vanvitelli“, Naples, Italy, ²Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, ³Division of Gastroenterology, „Federico II“ University, Naples, Italy, ⁴Gastroenterology and Endoscopy Unit, Immacolata Hospital, Sapri, Italy, ⁵Gastroenterology and Endoscopy Unit, S. Anna-S. Sebastiano Hospital, Caserta, Italy, ⁶Surgical Digestive Endoscopy, Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.

Friday

Saturday

Sponsored Symposium

Scientific Information

Acknowledgements

General Information



W3.5

Antibiotic-free Lipid Nanoparticles for Gastric Infection Management

C. L. Seabra^{1,2,3}, P. Parreira^{1,2}, P. Henriques^{1,2}, C. Monteiro^{1,2}, J. Gomes^{1,4}, I. Amorim^{1,4,5}, F. Gartner^{1,4,5}, C. Machado^{1,2}, C. Nunes⁶, S. Reis⁶, E. Touati⁷, C. A. Reis^{1,4,8}, I. C. Gonçalves^{1,2}, M. L. Martins^{1,2,5}, 1i3S- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal, 2INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal, 3CBQF- Centro de Biotecnologia e Química Fina, Universidade Católica Portuguesa (atual affiliation), Porto, Portugal, 4IPATIMUP – Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal, 5ICBAS- Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal, 6REQUIMTE, Laboratório de Química Aplicada, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal, 7Institut Pasteur, 25-28 Rue du Dr. Roux, 75015, Paris, France, 8Faculdade de Medicina, Universidade do Porto, Porto, Portugal.

W3.6

Fate of meta-analyses: the case of *Helicobacter pylori*

G. M. Buzás; Ferencváros Health Service Non-Profit Ltd, Budapest, Hungary.

W3.7

Pan-European Registry on *H. pylori* management (Hp-EuReg): Analysis of 4,388 second-line treatments

O. P. Nyssen¹, A. G. McNicholl¹, D. Vaira², A. Perez-Aisa³, B. Tepes⁴, D. S. Bordin⁵, F. Lerang⁶, T. Rokkas⁷, M. Leja⁸, A. Axon⁹, L. Kupcinkas¹⁰, L. Jonaitis¹⁰, J. Machado¹¹, O. Shvets¹², L. Veijola¹³, G. Buzás¹⁴, H. Simsek¹⁵, L. Boyanova¹⁶, V. Lamy¹⁷, Y. Niv¹⁸, M. Venerito¹⁹, P. Bytzer²⁰, L. G. Capelle²¹, A. Goldis²², K. Przytulski²³, C. Beglinger²⁴, M. Katicic²⁵, T. Milosavljevic²⁶, G. Fiorini², M. G. Donday¹, F. Megraud²⁷, C. O'Morain²⁸, J. P. Gisbert¹, 1H. La Princesa, IIS-IP and CIBERehd, Madrid, Spain, 2S. Orsola Malpighi Hospital, Bologna, Italy, 3Agencia Sanitaria Costa del Sol, Marbella, Spain, 4AM DC Rogaska, Rogaska Slatina, Slovenia, 5Moscow Clinical Scientific Center, Moscow, Russian Federation, 6Central Hospital Ostfold, Fredrikstad, Norway, 7Henry Dunant Hospital, Athens, Greece, 8Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia, 9University of Leeds, Leeds, United Kingdom, 10Lithuanian University of Health Sciences, Kaunas, Lithuania, 11Instituto de Investigação e Inovação em Saúde, Universidade do Porto, and Ipatimup - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal, 12Internal Diseases Department No.1, National Medical University named after O.O. Bogomolets, Kyiv, Ukraine, 13Internal Medicine, Herttoniemi Hospital, Helsinki, Finland, 14Ferencváros Polyclinic, Budapest, Hungary, 15Hacettepe University Faculty of Medicine, Ankara, Turkey, 16Medical University of Sofia, Sofia, Bulgaria, 17CHU Charleroi, Charleroi, Belgium, 18Rabin Medical Center, Tel Aviv University, Petach Tikva, Israel, 19Otto-von-Guericke University Hospital, Magdeburg, Germany, 20Zealand University Hospital, Copenhagen University, Copenhagen, Denmark, 21Erasmus MC University, Rotterdam, Netherlands, 22Timisoara Hospital, Timisoara, Romania, 23Medical Centre for Postgraduate Education, Warszawa, Poland, 24Medical Centre for Postgraduate Education, Warszawa, Poland, 25University Hospital Merkur Polyclinic Nola, Zagreb, Croatia, 26Clinical Center of Serbia Clinic for Gastroenterology and hepatology, University of Belgrade, Belgrade, Serbia, 27Hôpital Pellegrin, Bordeaux, France, 28Trinity College Dublin, Dublin, Ireland.

W3.8

Current treatment of *Helicobacter pylori* infected children and adolescents in Europe: Interim Results of the new EuroPedHp Registry

T. Le Thi¹, K. Werkstetter¹, J. Cabral², K. Kotile³, P. Bontems³, M. Cilleruelo Pascual⁴, J. Barrio⁵, M. Homan⁶, M. Kori⁷, P. Urruzuno⁸, N. Kalach⁹, Z. Misak¹⁰, R. Lima¹¹, M. Tavares¹¹, E. Miele¹², A. Chiaro¹³, V. Urbonas¹⁴, K. Matusiewicz¹⁵, A. Krah¹⁶, M. Korkut Ugras¹⁷, A. Papadopoulou¹⁸, F. Rea¹⁹, J. Sykora²⁰, J. de Laffolie²¹, M. Klemenak²², M. Rogalidou²³, E. Roma²⁴, A. Lopes²⁵, T. Casswall²⁶, A. Cseh²⁷, H. Banoub²⁸, S. Koletzko¹, and the *Helicobacter pylori* Working Group of ESPGHAN, 1Dr. von Hauner Children's Hospital, Medical center of the University of Munich, Munich, Germany, 2Hospital of Dona Estefania, CHLC, Lisbon, Portugal, 3Queen Fabiola Children's University Hospital, Brussels, Belgium, 4Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 5Hospital Universitario de Fuenlabrada Madrid, Madrid, Spain, 6University Children's Hospital Ljubljana, Ljubljana, Slovenia, 7Kaplan Medical Center Israel, Rehovot, Israel, 8Hospital Universitario Doce de Octubre, Madrid, Spain, 9Catholic University of Lille, Lille, France, 10Children's Hospital Zagreb, Zagreb, Croatia, 11Centro Hospitalar Universitário do Porto, Porto, Portugal, 12University of Naples 'Federico II', Naples, Italy, 13G. Gaslini Hospital in Genoa, Genoa, Italy, 14Vilnius University Children's Hospital, Vilnius, Lithuania, 15Wroclaw Medical University, Wroclaw, Poland, 16Children's Hospital Prinzessin Margaret, Darmstadt, Germany, 17Yeditepe University Hospital, Istanbul, Turkey, 18University of Athens Children's Hospital 'Agia Sofia', Athens, Greece, 19Bambino Gesù Children's Hospital, Rome, Italy, 20Charles University in Prague, Prague, Czech Republic, 21University Children's Hospital Giessen, Giessen, Germany, 22University Clinical Center Maribor, Maribor, Slovenia, 23University Hospital of Ioannina, Ioannina, Greece, 24Other Medical Centers in Athens, Athens, Greece, 25Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 26Karolinska University Hospital, Stockholm, Sweden, 27Semmelweis University, Budapest, Hungary, 28Epsom and St. Helier University Hospitals NHS Trust, Carshalton, United Kingdom.

17.30 - 19.15 hrs

Parallel Workshops from Submitted Abstracts 4

Workshop W4. | Gastric Carcinogenesis

Room Brussels

Chair: José Machado, Yaron Niv

Each presentation is scheduled for 12 minutes (9 min presentation + 3 min discussion)

- W4.1 **Understanding the tumour-promoting functions of autophagy in gastric carcinogenesis**
N. Castano Rodriguez¹, A. B. Goswami¹, I. Simovic¹, H. M. Mitchell¹, N. O. Kaakoush¹, K. M. Fock², K. L. Goh³, G. L. Porras-Hurtado⁴, J. L. Cardona-Deazza⁴, J. J. Montoya-Martinez⁴, A. J. Cadavid-Velez⁴, H. W. Toro-Hidalgo⁴, A. R. Cobo-Alvarado⁴, O. D. S. Hincapié-Rincón⁴, ¹The University of New South Wales, Sydney, Australia, ²Changi General Hospital, Singapore, Singapore, ³University of Malaya, Kuala Lumpur, Malaysia, ⁴Clinica Comfamiliar Risaralda, Pereira, Colombia.
- W4.2 **Molecular characterization of the gastric commensal bacteria progressing gastric carcinogenesis in *H. pylori*-infected gastric mucosa**
H. Tsugawa¹, J. Matsuzaki¹, H. Mori², M. Suematsu¹, H. Suzuki³, ¹Keio University, Tokyo, Japan, ²National Hospital Organization Tokyo Medical Center, Tokyo, Japan, ³Tokai University, Kanagawa, Japan.
- W4.3 **„*Helicobacter pylori*-activated gastric fibroblasts induce permanent reprogramming of gastric epithelial cells towards invasive phenotype in vitro“**
G. Krzysiek-Maczka¹, A. Targosz¹, M. Strzalka¹, U. Szczyrk¹, A. Ptak-Belowska¹, J. Czyz², T. Brzozowski¹, ¹Department of Physiology, Jagiellonian University Medical College, Cracow, Poland, ²Department of Cell Biology, the Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Cracow, Poland.
- W4.4 **Identification of novel serological biomarkers for gastric cancer in the MCC-Spain case-control study based on *Helicobacter pylori* whole-proteome microarrays**
R. Jeske¹, D. Reininger¹, J. A. Butt^{1,2}, C. Harmel¹, B. Turgu¹, N. Fernández de Larrea-Baz^{3,4}, V. Martín^{4,5}, V. Moreno^{4,6}, M. Kogevinas^{4,7}, M. Pollán^{3,4}, T. Waterboer¹, N. Aragonés^{4,8}, K. Hufnagel¹, ¹German Cancer Research Center (DKFZ), Heidelberg, Germany, ²Duke Cancer Institute and Duke University, Durham, NC, United States, ³National Center of Epidemiology, Carlos III Health Institute (ISCIII), Madrid, Spain, ⁴CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain, ⁵University of León, León, Spain, ⁶Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain, ⁷Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, ⁸Department of Health, Madrid, Spain.
- W4.5 **Risk of progression of intestinal metaplasia in a low gastric cancer incidence country.**
A. Bowden, J. Weininger, E. Farrell, S. Crowther, D. McNamara, C. O'Morain, A. O'Connor, Tallaght University Hospital/Trinity College Dublin, Dublin, Ireland.
- W4.6 **Prevention of *Helicobacter pylori*-associated gastric carcinogenesis with dietary walnut**
K. Hahm¹, Y. Shin², ¹CHA University, Seongnam, Republic of Korea, ²Inha University, Incheon, Republic of Korea.
- W4.7 **Role of Leukaemia Inhibitory Factor (LIF) on the tumorigenic properties of Cancer Stem Cells in gastric adenocarcinoma**
L. Seeneevassen¹, J. Giraud¹, S. Molina-Castro², C. Tiffon¹, C. Staedel³, O. Martin¹, F. Mégraud^{1,4}, P. Lehours^{1,4}, H. Boeuf⁵, P. Dubus^{1,4}, C. Varon¹, ¹INSERM U1053 BaRITOn, University of Bordeaux, Bordeaux, France, ²INISA-School of Medicine, University of Costa Rica, San José, Costa Rica, ³INSERM U1212 Régulations Naturelles et Artificielles des ARNs, University of Bordeaux, Bordeaux, France, ⁴CHU de Bordeaux, Bordeaux, France, ⁵INSERM U1026, Bordeaux, France.
- W4.8 **IL-27 is abrogated in the gastric mucosa and serum of patients with gastric cancer in opposite to duodenal ulcer**
D. M. M. Queiroz¹, F. F. Melo², M. M. D. A. Cabral¹, B. B. Brito², F. A. F. Silva², G. A. Rocha¹, ¹Universidade Federal de Minas Gerais/Faculdade de Medicina, Belo Horizonte, Brazil, ²Universidade Federal da Bahia, Vitória da Conquista, Brazil.

20.00 hrs

Networking Dinner at the Restaurant Stiftskeller



PROGRAMME SATURDAY, SEPTEMBER 7

18

08.00 - 09.40 hrs

Symposium: Modulation of microbiota

Room Innsbruck

Chair: Georgina Hold, Patrizia Kump

08.00 - 08.20

Diet: a major confounder of the gut microbiota

Alexander Moschen, Innsbruck, Austria

08.20 - 08.40

Probiotics – how and when do they work?

Mirjana Rajilic-Stojanovic, Belgrade, Serbia

08.40 - 09.00

Pre-/pro-/antibiotics: how to best manipulate the microbiota?

Laure Bindels, Louvain, Belgium

09.00 – 09.20

FMT: indications and potential

Gianluca Ianiro, Rome, Italy

09.20 - 09.40

New Stool Biobanking Initiative

Josbert Keller, Den Haag, The Netherlands

09.40 – 10.30 hrs

Coffee Break

10.30 - 11.50 hrs

Symposium: Helicobacter and other Microbiota in Extragastric Diseases

Room Innsbruck

Chair: Antonio Gasbarrini, Alexander Moschen

10.30 - 10.50

Autoimmune & Allergic Disorders

Maria Pina Doré, Sassari, Italy

10.50 - 11.10

Metabolic Syndrome & Asthma

Nayoung Kim, Seoul, Korea

11.10 - 11.30

Atherothrombosis

Christoph Reinhardt, Mainz, Germany

11.30 - 11.50

Neurodegenerative diseases

Claire Roubaud, Bordeaux, France

12.00 - 13.00 hrs

Symposium: Modulation of microbiota

Chair: David Graham

Please see page 22 for details

13.00 - 14.00 hrs

Lunch Break & Poster Viewing

14.00 - 15.30 hrs

Parallel Workshops from Submitted Abstracts 5 Workshop W5. | Treatment of Helicobacter Infection II

Room Innsbruck

Chair: Javier Gisbert, Athanasios Makrithatis

Each presentation is scheduled for 12 minutes (9 min presentation + 3 min discussion)

W5.1

Helicobacter pylori Acid Acclimation: The Evil Duo of a pH-Gated Urea Channel and a Cytoplasmic Urease

H. L. Luecke, E. Cunha, University of Oslo, Oslo, Norway.

- W5.2 **Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of *Helicobacter pylori***
T. Furuta, M. Yamade, T. Kagami, T. Suzuki, T. Higuchi, T. Uotani, S. Tani, M. Iwaizumi, Y. Hamaya, S. Osawa, K. Sugimoto, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- W5.3 **Ten-day concomitant, 10-day sequential, and 7-day triple therapy in first-line treatment of *Helicobacter pylori* infection: a randomized nationwide trial in Korea**
B. Kim¹, H. Lee², J. Kim¹, J. Kim², Korean College of Helicobacter and Upper Gastrointestinal Research, 1Chung-Ang University Hospital, Seoul, Republic of Korea, 2SungKyunKwan University College of Medicine, Seoul, Republic of Korea.
- W5.4 **Effect of Previous Nitroimidazole Treatment on *Helicobacter pylori* Eradication Success**
D. Boltin¹, Z. Levi¹, R. Gingold-Belfer¹, T. Shochat¹, I. Dotan¹, S. Birkenfeld², Y. Niv³, 1Rabin Medical Center, Petah Tikva, Israel, 2Clalit Health Services, Tel Aviv, Israel, 3Ministry of Health, Jerusalem, Israel.
- W5.5 **Growing *H. pylori* resistance to standard antibiotictherapies identified from a phase 3 clinical trial of treatment naive patients in the United States**
D. Y. Graham¹, K. G. Hulten¹, L. B. Lamberth¹, R. M. Panas², I. N. Kalfus³, 1Baylor College of Medicine, Houston, TX, United States, 2RedHill Biopharma, Inc., Raleigh, NC, United States, 3RedHill Biopharma, Ltd., Tel Aviv, Israel.
- W5.6 **European survey of *Helicobacter pylori* primary resistance to antibiotics - Evolution over the last 20 years**
F. Mégraud¹, D. Huang², M. Hoebeke², C. Alix¹, L. Bénéjat¹, P. Lehours¹, Y. Glupczynski², The H. pylori AST Working Group, 1National Reference Centre for Helicobacters, Bacteriology Laboratory, Pellegrin Hospital, Bordeaux, France, 2National Reference Centre for Helicobacters, Bacteriology Laboratory, CHU UCL Namur (Site Godinne), Yvoir, Belgium.
- W5.7 **The activity of liposomal linolenic acid against *Helicobacter pylori* in vitro and its impact on human fecal microbiota**
Y. Wang^{1,2}, S. Wu¹, Y. An^{1,2}, Y. Wang¹, Y. He¹, Y. Fu³, Y. Xie¹, 1Department of Gastroenterology, Nanchang, China; 2School of Pharmacy, Nanchang University, Nanchang, China; 3School of Pharmacy, Nanchang, University, Nanchang, Nanchang, China

14.00 - 15.30 hrs

Parallel Workshops from Submitted Abstracts 6 Workshop W6. | Microbiota in Health and Disease

Room Brussels

Chair: Josbert Keller, Mirjana Rajilić-Stojanović

Each presentation is scheduled for 12 minutes (9 min presentation + 3 min discussion)

- W6.1 **Functional Microbiomics - Standardized Assessment of Nutrition-Microbiome-Host Interplay by Targeted Metabolomics**
H. Pham Tuan, U. Sommer, D. Kirchberg, X. Iwanowa, R. Talmazan, M. Buratti, B. Wolf, T. Koal, W. Fischer-Knuppertz, BIOCRATES Life Sciences, Innsbruck, Austria.
- W6.2 **Combining nucleic acid mimics and spectral imaging with fluorescence in situ hybridization for the analysis of the gastric micro-biogeography**
A. S. Azevedo^{1,2,3}, H. Teixeira¹, R. Ferreira^{2,3}, C. Figueiredo^{2,3}, J. Wengel⁴, C. Almeida^{1,5,6}, N. Azevedo¹, 1LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465, Porto, Portugal, 2i3S Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal, 3IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal, 4Nucleic Acid Center, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark, 5National Institute for Agrarian and Veterinary Research (INIAV), Rua dos Lagidos, Lugar da Madalena, 4485-655 Vairão, Vila do Conde, Portugal, 6Centre of Biological Engineering, Universidade do Minho, Campus de Gualtar, 4710-057, Braga, Portugal.
- W6.3 **Patients with small intestinal bacterial overgrowth (SIBO) have distinct microbiome characteristics including post *Helicobacter pylori* eradication treatment**
T. T. Perets^{1,2}, O. Ashorov¹, D. Hamouda¹, S. Ben Simon³, D. Boltin^{4,2}, O. Koren³, R. Dickman^{4,2}, 1Rabin Medical Center - Gastroenterology Laboratory, Petah Tikva, Israel, 2Tel Aviv University - Sackler Faculty of Medicine, Tel Aviv, Israel, 3Bar Ilan University - Azrieli Faculty of Medicine, Zefat, Israel, 4Rabin Medical Center - Division of Gastroenterology, Petah Tikva, Israel.



- W6.4 The difference of gut microbiome in the stage of colorectal cancer and change of gut microbiome after surgery or chemotherapy**
J. Cho¹, D. Lee^{1,2}, Y. Lee², M. Seol², Y. Kim³, W. Lee⁴, Y. Kim⁴, Y. Park¹, C. Shin¹, H. Yoon¹, N. Kim¹, S. Seol⁵, 1Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 2R&D center, BioBankHealing Inc., Seongnam, Republic of Korea, 3Graduate School of Medical Science & Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, 4MD Healthcare Inc., Seoul, Republic of Korea, 5Inje University Busan Paik Hospital, Busan, Republic of Korea.
- W6.5 Microbiota changes induced by Microencapsulated Sodium Butyrate**
S. Facchin¹, N. Vitulo², M. Calgaro², A. Buda³, R. Chiara⁴, B. Perini¹, G. Lorenzon¹, C. Marinelli¹, E. Savarino¹, 1University of Padua, DiSCOG, Padua, Italy, Padua, Italy, 2University of Verona, Department of Biotechnology, Verona, Italy, 3UOC Gastroenterology, Feltre, Belluno, Italy, 4University of Padua, Department of Biology, Padua, Italy.
- W6.6 Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome**
P. Cardenas¹, M. Baldeon², H. Cohen³, M. Fornasini⁴, D. Garces⁵, B. Prado⁵, N. Flores⁴, I. Salvador⁴, O. Cargua⁴, 1Instituto de Microbiologia - Universidad San Francisco de Quito, Quito, Ecuador, 2CENBIO - Universidad UTE, Quito, Ecuador, 3Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, 4CENBIO, Quito, Ecuador, 5Instituto de Microbiologia, Quito, Ecuador.
- W6.7 Efficacy and safety of new Lactobacilli mixture in patients with unconstipated irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial**
O. Joo Hyun¹, Y. Jang¹, D. Kang^{2,3}, D. Chang¹, Y. Min¹, 1Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea, 2Department of Clinical Research Design and Evaluation, Samsung Medical Center, Seoul, Republic of Korea, 3Center of Clinical Epidemiology, Samsung Medical Center, Seoul, Republic of Korea.

15.30 – 16.00 hrs

Coffee Break

16.00 - 17.30 hrs

Symposium: Treatment of *H. pylori* infection

Room Innsbruck

Chair: Jyhming Liou, Peter Malfertheiner

16.00 - 16.20

Efficacy of empirical vs. guided treatment
Liou JM, Taipei, Taiwan

16.20 - 16.50

Monitoring antibiotic resistance, when and how?
A French perspective
Francis Mégraud, Bordeaux, France

A Korean perspective
Hwoon-Yong Jung, Seoul, Korea

16.50 - 17.10

Where are we with a vaccine?
David Graham, Houston, TX, USA

17.10 - 17.30

Beyond antibiotics
Niyaz Ahmed, Dhaka, Bangladesh

17.30 - 18.00 hrs

Debate: Is *Helicobacter pylori* relevant in oesophageal diseases?

Chair: Günter Krejs, Colm O'Morain

Room Innsbruck

Yes

Francesco Di Mario, Parma, Italy

No

Peter Malfertheiner, Munich, Germany

18.00 - 18.30 hrs

Closing Session

Chair: Georgina Hold, Francis Mégraud, Herbert Tilg

Room Innsbruck

Awarding of the Marshall and Warren Medal to Guillermo Perez-Perez

EHMSG Presentation and Poster Awards

Presentation of the next meeting in Glasgow, United Kingdom

Closing remarks



Friday

Saturday

Sponsored Symposium

Scientific Information

Acknowledgements

General Information



Saturday, September 7, 2019

12.00 - 13.00 hrs

Industry Sponsored Satellite Symposium

Room Innsbruck

***H.pylori* treatment and Microbiome research in China**

Chair: David Graham, Houston, TX, USA

12.00 - 12.20 hrs

Bismuth plus triple therapy adjusted according to medication history in the first-line eradication of *Helicobacter pylori* infection: a randomized trial
Prof. Liya Zhou

12.20 - 12.40 hrs

The management of drug resistant *Helicobacter pylori* in China
Prof. Rong Lin

12.40 - 13.00 hrs

***Helicobacter Pylori*, Microbiome and Gastric Cancer**
Prof. Jun Yu

 **RICHEN EUROPE S.R.L.**
COMPANY OF RICHEN GROUP



Oral Presentations

Commercial Disclosure information

Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

If you have nothing to disclose, please state "I have no commercial disclosure" instead of the table.

Speaking Time

The chairpersons of your session will be strict in allowing no more than the time allotted to your presentation. Remember to allow some time for the changeover of speakers and chairperson's introduction, and for questions and discussion.

Make yourself known to the chairpersons and/or the technician in your session room before the beginning of the session.

Projection and Technical Settings

All rooms are equipped with Windows 10 and data projector for Power Point presentation (PPT 2016) only.

Presentation Format 16:9

Handing in Your Presentation:

It must then be handed over to the technician of the according lecture room in a break at least 2 hours before your talk either via USB-Memory Stick or USB-External Drives (30 minutes for talks in the first morning sessions).

General hints and tips

Like all of us, you will have sat through many conference talks, some good and some bad. We have all been to talks which failed to communicate their message because the speaker spoke impossibly fast, perhaps in a very indistinct way, or flashed through large numbers of slides so crammed with detail that nobody could follow them.

So please:

- Make yourself known to the chairpersons and/or the room assistant in your session room before the beginning of the session.
- Remember that the vast majority of the audience are not native English speakers - speak clearly (whether or not English is your native tongue) and not too fast
- Plan an average of no more than 1 slide per minute, in most cases
- Keep your Powerpoints simple. In text slides, use no more than ten lines per slide, with ample space between the lines, and no more than seven words per line in suitably large lettering
- Leave sufficient space between the text and the edge of the slide/screen.
Some data projectors may not display the very border of the slide/presentation.



Poster Presentations

IMPORTANT NOTE: Posters are on display for two days. Posters need to be taken off by the author at the end of the conference. Posters not removed until then will be removed by the staff. Posters will be discarded, and neither kept, stored nor sent to the authors after the meeting.

Please note that the organisers cannot assume any liability for loss, theft or damage of posters displayed in the poster area.

Mounting of posters is possible on Friday, September 6, 2019 from 8.00 - 10.00 hrs.

Removal on Saturday, September 7, 2019, from 15.00-17.30 hrs.

You will find your poster board number in the author index of the abstract book, which you have received at the registration desk.

The presence at the poster of *one* of the authors is mandatory during the following times:

Friday, September 6, 2019

Poster Round 1

Treatment of Helicobacter infection- P1.1 (P1.01 - P1.52)

Drug resistance and Clinical Issues P1.2 (P1.53 - P1.70)

Chairs: Anthony Axon, Dmitry Bordin, Javier P. Gisbert, David Graham, Limas Kupcinskas, Athanasios Makrithatis, Olga Nyssen, Christian Schulz

Poster Round 2

Helicobacter and extragastrointestinal disease P2.1 (P2.01 - P2.11)

Gastric microbiota P2.2 (P2.12 - P2.19)

Chairs: Ceu Figueiredo, Juozas Kupcinskas

Poster Round 3:

Gut microbiota in health and disease P3.1 (P3.01 - P3.38)

Chairs: Timon-Erik Adolph, Gianluca Ianiro, Francesco Franceschi, Patrizia Kump, Patricia Lepage, Alexander Moschen

Saturday, September 7, 2019

Poster Round 4:

01. Diagnosis of Helicobacter infection P4.1 (P4.01 - P4.14)

06. Epidemiology P 4.2 (P4.15 - P4.31)

10. Paediatrics P4.3 (P4.32-P4.42)

Chairs: Leif P. Andersen, Luiz Coelho, Marcis Leja, Maria Effenberger, Varocha Mahachai, Francis Mégraud

Poster Round 5:

04. Gastric cancer and cancerogenesis P5.1 (P5.01 - P5.37)

Chairs: José C. Machado, Ari P. Ristimäki, Massimo Rugge, Chung-Ying Wu

Poster Round 6:

05. Virulence factors and pathogenesis of Helicobacter infection P6.1 (P6.01 - P6.19)

07. Inflammation, immunity, vaccines and host interaction P6.2 (P6.20 - P6.32)

08. Microbiology and genomics of Helicobacter P6.3 (P6.33 - P6.36)

Chairs: Niyaz Ahmed, Mario Milco D'Elis, James G. Fox, Yoshio Yamaoka

Format

The usable surface on the poster board is 90 cm width x 150 cm height (portrait format).

Adhesive material will be made available.

Acknowledgements

The organisers gratefully acknowledge the support of the following institutions and companies for the EHMSG 2019 Workshop:



The organisers gratefully acknowledge the support of the following company for the EHMSG 2019 Postgraduate Course:





In alphabetical order.

Badges

Participants should collect name badges from the conference registration desk. As only registered participants will be permitted to attend the Scientific Sessions, the Exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue.

Cancellations and Refunds

Notice of cancellation had to be made in writing by email or fax to the Congress Office.

The policy for refunding registration fees is as follows:

Written cancellation received:

- Before July 31, 2019: 50% refund

- After July 31, 2019: no refund

The date of the email or fax ID is the basis for considering refunds. Refunds will be made after the congress.

Certificate of Attendance

Confirmations of attendance will be issued at the registration desk.

Cash Dispensers

ATMs are widely available in Innsbruck. Local currency (Euro) can also be obtained from banks and exchange bureaus.

CME Credits

The "XXXIInd International Workshop on Helicobacter and Microbiota in Inflammation and Cancer" was granted a total of **14 European CME credits** (ECMEC) the Postgraduate Course on "Microbiota: from metabolism to immunity and faecal microbial transplantation-pearls for the clinician" was granted a total of **6 European CME credits** (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Coffee Breaks and Lunch

During the session breaks refreshments (coffee, tea, and water) will be served free of charge to participants wearing name badges. Lunch tickets for Friday and Saturday had to be pre-ordered and cannot be purchased on site. Lunch tickets are not refundable.

Congress Venue

XXXIInd Workshop of the EHMSG:

Congress Innsbruck

Rennweg 3

6020 Innsbruck, Austria

Currency

The official currency of Austria is the Euro (EUR).

1 EUR = 1,12 USD = 0,93 GBP = 129 JPY = 1,08 CHF = 10,69 SEK = 7,46 DKK = 1,65 AUD = 1,48 CAD

as per date of printing

Electricity Supply

In Austria the **standard** voltage is 230 V and the frequency is 50 Hz. You can use your electric appliances in Austria, if the **standard** voltage in your country is in between 220 - 240 V (as is in the UK, Europe, Australia and most of Asia and Africa). Socket Type F („Schuko“)

GSM cell phone roaming

GSM cell/mobile phone roaming is available without any problems for all major international providers. It is advisable to inquire at your provider which roaming company in Austria offers the cheapest tariffs for non-EU contracts.

Internet

You will find Internet cafés throughout the city.

WIFI is available at the conference venue please use the ehmsg2019 for username and password

Language

The official language of the workshop is English (no simultaneous translation).

Liability

In registering for the EHMSG 2019 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements in respect of health and travel. Furthermore, the organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

Opening hours of the Exhibition at the Conference venue

EHMSG Postgraduate Course & EHMSG Far East Symposium

Thursday, September 5, 2019: 07.30 – 19.00 hrs

EHMSG Workshop

Friday, September 6, 2019: 07.30 – 19.15 hrs

Saturday, September 7, 2019: 07.30 – 18.30 hrs

Poster Removal

The organisers cannot assume any liability for loss or damage of posters displayed in the poster area. Posters that were not removed after the end of the respective day of display, will be removed and will not be kept nor mailed to the author after the meeting. See detailed information in the “scientific information” section of the program.

Presentations

All presenters should hand in their electronic presentation to the technician of the according lecture room in a break at least 2 hours before your talk either via USB-Memory Stick or USB-External Drives (30 minutes for talks in the first morning sessions).

Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide.

A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

If you have nothing to disclose, please state “I have no commercial disclosure” instead of the table.

Safety - Crime

Visitor safety is generally adequate, like in any other major European city. You can walk everywhere using common sense. Pick pocketing in heavily visited tourist zones or in public transport lines might be a concern.

Unfortunately experience has shown that some basic precautionary measures should always be kept in mind in any city:

- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay. Rather carry a Xerox copy of your passport or an identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag. If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference venue, it will make you easily identifiable as a tourist.

Smoking Policy

The EHMSG 2019 Workshop is a “No-smoking-Conference”.

Staff

If you should have any questions, the congress staff will be pleased to help you.



Registration Details

Registration Fees

Payment received	Before July 12, 2019	After July 12, 2019 & on site
Regular Participants	EUR 320.–	EUR 420.–
Young Scientists (<35 years)	EUR 170.–	EUR 220.–
Students (< 30 years)	EUR 110.–	EUR 110.–
Company Representatives	EUR 450.–	EUR 550.–
Member of the Paediatric Task Force	EUR 220.–	EUR 250.–
Day Ticket - Regular / Young Scientist / Student	-	EUR 220.– / 145.– / 80.–
Postgraduate Course ONLY	EUR 150.–	EUR 170.–
Combined Fee EHMSG & Postgraduate Course - Regular Participants	EUR 420.–	EUR 520.–
Combined Fee EHMSG & Postgraduate Course - Young Scientists	EUR 270.–	EUR 320.–
Combined Fee EHMSG & Postgraduate Course - Students	EUR 210.–	EUR 210.–
Combined Fee EHMSG & Postgraduate Course - Company Representatives	EUR 550.–	EUR 650.–
Combined Fee EHMSG & Postgraduate Course - Paediatric Task Force	EUR 320.–	EUR 350.–
Networking Event, September 5, 2019	---*	---*
Networking Dinner, September 6, 2019	EUR 65.–	EUR 65.–**
Lunch tickets (per day)	EUR 15.–	---***

* no fee but registration is mandatory. registering for tickets on site is subject to availability

** Purchasing tickets on site is subject to availability

*** Lunch tickets had to be pre-ordered and cannot be purchased on site

Payment of Registration fees may be made either cash in Euro or by Credit Card (Diners Club, Mastercard and Visa).

Please note

The reduced registration fee was only applicable, **if it has been credited to the congress account before the deadline.** Registering before July 12, 2019 without performing an actual payment was not sufficient to benefit from the reduction.

What is covered by the registration fee?

- Admission to all scientific sessions and the exhibition
- Admission to the networking mixer (subject to availability)
- Programme book
- Abstract Book
- Refreshments during coffee breaks

Networking Events

Thursday, September 5, 2019, 19.00 hrs

Networking Event at the Conference Venue

Free for registered participants, however registration for this event is mandatory.



Friday, September 6, 2019, 20.00 hrs

EHMSG Networking Evening at the Restaurant Stiftskeller

A ticket is required and will be checked at the entrance - EUR 65,- per ticket





When something happens
in the microbiota realm,
**you can be sure
to find it online.**



Biocodex, a French laboratory with an international scope, has launched a reference website for the human microbiota. On BMI-PRO.com, you'll find essential information to help you better understand microbiota and find out how they interact with diseases. You'll also get the latest news and learn about every exciting new discovery.

Master microbiota? With BMI-PRO.com, you can.

BIOCODEX 
Microbiota Institute

New Instruments Generations in Breath Test Analysis

THE EVOLUTION OF THE SPECIES



IR-FORCE 200 Android



IR-FORCE 200 Fancy



IR-FORCE 300 Plus

Helicobacter Test INFAl®

One of the most used ^{13}C -urea breath tests for the diagnosis of Hp-infections worldwide



- New line of INFAl packaging according the EU's Falsified Medicines Directive
- More than 6.4 million Helicobacter Test INFAl performed worldwide
- Registered in more than 40 countries worldwide
- First approved Hp test for children from the ages of 3 to 11
- Modified Hp test for patients taking PPIs (REFEX)
- Cost-effective CliniPac Basic for hospital and GPs use



INFAl GmbH
Gottfried-Hagen Straße 60-62
D-51105 Cologne

Phone: +49 221 880 44-3
Fax: +49 221 880 44-55
Email: mail@infai.de, info@infai.co.uk
Web: www.infai.de, www.infai.co.uk